0001354457-22-000754.txt : 20221221
0001354457-22-000754.hdr.sgml : 20221221
20221221060804
ACCESSION NUMBER: 0001354457-22-000754
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20221221
DATE AS OF CHANGE: 20221221
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001169245
PhaseBio Pharmaceuticals Inc
001-38697
1 Great Valley Parkway
Suite 30
Malvern
PA
PENNSYLVANIA
19355
(610) 981-6509
Common Stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2022-12-21
EX-99.25
2
phasdelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, December 21, 2022,
PhaseBio Pharmaceuticals, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the common stock of PhaseBio Pharmaceuticals, Inc.,
effective at the opening of the trading session on January 3, 2023.
Based on review of information provided by the Company, Exchange Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rules 5101, 5110(b), and IM-5101-1.
The Company was notified of the Staff determination on October 25,
2022. The Company did not appeal the Staff determination to the Hearings
Panel. The Staff determination to delist the Company securities became
final on November 3, 2022.